| Market Capitalization (Millions $) |
735 |
| Shares
Outstanding (Millions) |
167 |
| Employees |
100 |
| Revenues (TTM) (Millions $) |
362 |
| Net Income (TTM) (Millions $) |
102 |
| Cash Flow (TTM) (Millions $) |
112 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Ironwood Pharmaceuticals Inc. is an American pharmaceutical company, founded in 1998, and is headquartered in Cambridge, Massachusetts. The company specializes in the development and commercialization of drugs to treat gastrointestinal disorders, including irritable bowel syndrome, acid reflux, and refractory gastroesophageal reflux disease.
Ironwood Pharmaceuticals Inc. has a broad range of products that are used in the treatment of gastrointestinal disorders, including medications like Linzess, Zelnorm, and Zurampic. Ironwood's lead product, Linzess, is approved by the FDA for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It works by regulating the activity of specific receptors in the gut, improving motility and reducing pain.
Ironwood Pharmaceuticals Inc. is committed to developing innovative solutions for gastrointestinal disorders. As such, it is actively involved in the research and clinical development of potential new treatments to address unmet medical needs. In 2014, Ironwood Pharmaceuticals Inc. entered into a strategic collaboration with AstraZeneca to develop and commercialize lesinurad, a potential treatment for gout.
Ironwood Pharmaceuticals Inc. has a dedicated team of over 500 employees who work together to advance the company's vision of transforming the treatment of gastrointestinal disorders. The company has a history of investing in research and development, and as of 2021, had over 150 patents and patent applications in the United States.
Ironwood Pharmaceuticals Inc. is also committed to giving back to the community. In 2020, the company announced a donation of $1 million to support organizations working to address racial injustice and health disparities in the United States.
In conclusion, Ironwood Pharmaceuticals Inc. is a pharmaceutical company focused on developing treatments for gastrointestinal disorders. With a broad range of products, a strong portfolio of patents, and a commitment to innovation and community engagement, Ironwood Pharmaceuticals Inc. is well-positioned to make a positive impact on the lives of patients with gastrointestinal disorders.
Company Address: 100 Summer Street Boston 2110 MA
Company Phone Number: 621-7722 Stock Exchange / Ticker: NASDAQ IRWD
|
7.81% 
0.75 %